- Home
- JG vs IFRX Comparison
JG vs IFRX Comparison
Compare JG & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JG
- IFRX
- Stock Information
- Founded
- JG 2012
- IFRX 2007
- Country
- JG China
- IFRX Germany
- Employees
- JG N/A
- IFRX N/A
- Industry
- JG Computer Software: Programming Data Processing
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- JG Technology
- IFRX Health Care
- Exchange
- JG Nasdaq
- IFRX Nasdaq
- Market Cap
- JG 48.4M
- IFRX 53.5M
- IPO Year
- JG 2018
- IFRX 2017
- Fundamental
- Price
- JG $8.52
- IFRX $1.43
- Analyst Decision
- JG
- IFRX Strong Buy
- Analyst Count
- JG 0
- IFRX 5
- Target Price
- JG N/A
- IFRX $7.40
- AVG Volume (30 Days)
- JG 11.0K
- IFRX 492.5K
- Earning Date
- JG 11-13-2025
- IFRX 11-07-2025
- Dividend Yield
- JG N/A
- IFRX N/A
- EPS Growth
- JG N/A
- IFRX N/A
- EPS
- JG N/A
- IFRX N/A
- Revenue
- JG $48,999,972.00
- IFRX $191,224.00
- Revenue This Year
- JG $10.90
- IFRX N/A
- Revenue Next Year
- JG N/A
- IFRX $1,216.24
- P/E Ratio
- JG N/A
- IFRX N/A
- Revenue Growth
- JG 18.82
- IFRX 54.36
- 52 Week Low
- JG $4.25
- IFRX $0.71
- 52 Week High
- JG $20.94
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- JG 40.59
- IFRX 55.06
- Support Level
- JG $8.02
- IFRX $1.29
- Resistance Level
- JG $9.33
- IFRX $1.44
- Average True Range (ATR)
- JG 0.41
- IFRX 0.14
- MACD
- JG -0.03
- IFRX -0.00
- Stochastic Oscillator
- JG 34.11
- IFRX 48.84
About JG Aurora Mobile Limited
Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates and generates its revenue from the People's Republic of China.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.